Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

64.40EUR
11:35am EST
Change (% chg)

€0.07 (+0.11%)
Prev Close
€64.33
Open
€64.55
Day's High
€64.80
Day's Low
€63.88
Volume
2,472,907
Avg. Vol
4,134,163
52-wk High
€108.47
52-wk Low
€60.27

Latest Key Developments (Source: Significant Developments)

German Chemicals Association Sees 2019 Sales Rising By 2.5 Pct
Tuesday, 4 Dec 2018 05:00am EST 

Dec 4 (Reuters) - German chemicals association VCI::SEES 2019 SALES +2.5 PERCENT, PRICES +1.0 PERCENT, PRODUCTION +1.5 PERCENT.SEES 2018 PRODUCTION +2.5 PERCENT (VERSUS PREVIOUS F'CAST OF +3.5 PERCENT), PRICES +2.0 PERCENT (VERSUS PREVIOUS F'CAST +1.5 PERCENT), SALES STILL AT +4.5 PERCENT.  Full Article

Bayer: FDA Grants Breakthrough Device Designation To AI Software For CTEPH Pattern Recognition
Monday, 3 Dec 2018 07:58am EST 

Dec 3 (Reuters) - Bayer AG ::FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO ARTIFICIAL INTELLIGENCE SOFTWARE FOR CTEPH PATTERN RECOGNITION FROM BAYER AND MSD.  Full Article

Bayer - Intends To Exit Animal Health Business, Cut 12,000 Jobs
Thursday, 29 Nov 2018 08:45am EST 

Nov 29 (Reuters) - Bayer AG ::BAYER TO STRENGTHEN CORE LIFE SCIENCE BUSINESSES WHILE SIGNIFICANTLY ENHANCING PRODUCTIVITY AND PROFITABILITY.AIMS TO STRENGTHEN ITS CORE LIFE SCIENCE BUSINESSES THROUGH A SERIES OF PORTFOLIO, EFFICIENCY AND STRUCTURAL MEASURES DESIGNED TO ENHANCE PRODUCTIVITY AND INNOVATION WHILE SIGNIFICANTLY IMPROVING COMPETITIVENESS.SUPERVISORY BOARD OF BAYER AG DISCUSSED PLANS LAID OUT BY BOARD OF MANAGEMENT AND UNANIMOUSLY EXPRESSED THEIR SUPPORT.IS IN DISCUSSIONS REGARDING DIVESTMENT OF ITS 60-PERCENT INTEREST IN GERMAN SITE SERVICES PROVIDER CURRENTA..INTENDS TO EXIT ANIMAL HEALTH BUSINESS AND IS ASSESSING AVAILABLE OPTIONS.AT CROP SCIENCE DIVISION, FOCUS IS ON SUCCESSFULLY INTEGRATING ACQUIRED BUSINESS. AS PREVIOUSLY COMMUNICATED, BAYER EXPECTS SYNERGIES TO DELIVER ANNUAL CONTRIBUTIONS OF 1.04 BILLION TO EBITDA.ALTHOUGH THIS UNIT OFFERS GROWTH OPTIONS IN AN ATTRACTIVE MARKET, BAYER INTENDS TO ALLOCATE INVESTMENT RESOURCES NECESSARY TO SUPPORT ANIMAL HEALTH TO BAYER'S CORE BUSINESSES OF PHARMACEUTICALS, CONSUMER HEALTH AND CROP SCIENCE.AT CONSUMER HEALTH, COMPANY HAS INITIATED MEASURES TO ENABLE DIVISION TO CATCH UP TO MARKET GROWTH IN COMING YEARS AND IMPROVE PROFITABILITY.AT CONSUMER HEALTH AND PHARMACEUTICALS DIVISIONS, NON-CASH IMPAIRMENTS AND WRITE-OFFS TOTALING APPROXIMATELY 3.3 BILLION EUROS ARE ANTICIPATED IN Q4 OF 2018.  Full Article

Bayer Receives EU Approval For Its Hemophilia A Treatment Jivi
Tuesday, 27 Nov 2018 09:32am EST 

Nov 27 (Reuters) - Bayer AG ::BAYER RECEIVES EU APPROVAL FOR ITS HEMOPHILIA A TREATMENT JIVI.APPROVAL IS BASED ON RESULTS FROM THE PROTECT VIII TRIAL.  Full Article

Bayer Receives EU Approval For Hemophilia A Treatment Jivi
Tuesday, 27 Nov 2018 09:30am EST 

Nov 27 (Reuters) - Bayer AG ::RECEIVES EU APPROVAL FOR HEMOPHILIA A TREATMENT JIVI.  Full Article

Bayer Says To Offer Access To Its Glyphosate Studies
Wednesday, 21 Nov 2018 03:19am EST 

Nov 21 (Reuters) - Bayer AG ::BAYER TO OFFER ACCESS TO ITS OWNED GLYPHOSATE STUDIES.WILL SOON INCLUDE SAFETY STUDY SUMMARIES OF GLYPHOSATE ON ITS DEDICATED TRANSPARENCY PLATFORM.  Full Article

Bayer Appeals At Court On Monsanto Weed-Killer Litigation
Wednesday, 21 Nov 2018 02:30am EST 

Nov 21 (Reuters) - Bayer AG ::ON DEWAYNE JOHNSON V. MONSANTO WEED-KILLER LITIGATION - HAVE APPEALED AT CALIFORNIA COURT OF APPEAL.ON WEED-KILLER LITIGATION - SCIENTIFIC DATA SUBMITTED TO COURT DOES NOT SUPPORT CONCLUSION THAT THERE IS A RELEVANT LINK BETWEEN USE OF GLYPHOSATE OR ROUNDUP AND NON-HODGKIN'S LYMPHOMA IN PLAINTIFF.  Full Article

Bayer AG Receives Approval For Hemophilia A Treatment Jivi
Wednesday, 24 Oct 2018 09:56am EDT 

Oct 24 (Reuters) - Bayer AG ::BAYER AG - RECEIVES APPROVAL FOR HEMOPHILIA A TREATMENT JIVI.BAYER - HEALTH CANADA ALSO APPROVED JIVI FOR CONTROL AND PREVENTION OF EPISODIC BLEEDING, AND PERI-OPERATIVE MANAGEMENT OF BLEEDING.BAYER - RECOMMENDED INITIAL PROPHYLACTIC REGIMEN FOR JIVI IS TWICE WEEKLY.  Full Article

Orion And Bayer Have Completed Phase III Trial with The Primary Endpoint Was Met
Wednesday, 24 Oct 2018 01:30am EDT 

Oct 24 (Reuters) - Orion Oyj ::REG-ORION AND BAYER HAVE COMPLETED THE PHASE III TRIAL OF DAROLUTAMIDE IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - THE PRIMARY ENDPOINT WAS MET.DAROLUTAMIDE SIGNIFICANTLY EXTENDED METASTASIS-FREE SURVIVAL COMPARED TO PLACEBO..SAFETY PROFILE AND TOLERABILITY OF DAROLUTAMIDE OBSERVED IN ARAMIS TRIAL WERE CONSISTENT WITH DATA ON DAROLUTAMIDE.BAYER PLANS TO DISCUSS DATA FROM ARAMIS TRIAL WITH HEALTH AUTHORITIES.  Full Article

Greenlight Capital Exits Apple, Says Tesla Short Its Second Biggest Winner In Qtr
Friday, 5 Oct 2018 01:05pm EDT 

Oct 5 (Reuters) - Greenlight Capital::GREENLIGHT CAPITAL SAYS HAD A DIFFICULT QUARTER AND LOST AN ADDITIONAL 9.1 PERCENT THAT BRINGS YTD LOSSES TO 25.7 PERCENT - LETTER.GREENLIGHT CAPITAL SAYS ON AUG 31, SOLD LAST OF ITS APPLE STOCK AT $228 PER SHARE.GREENLIGHT CAPITAL SAYS ITS APPLE INVESTMENT COMPOUNDED ANNUALLY AT 26 PERCENT & EARNED IT OVER $1 BILLION.GREENLIGHT CAPITAL SAYS ITS TESLA SHORT WAS SECOND BIGGEST WINNER DURING THE QUARTER.GREENLIGHT CAPITAL SAYS ITS BRIGHTHOUSE FINANCIAL SHORT WAS ITS BIGGEST WINNER DURING THE QUARTER.GREENLIGHT CAPITAL SAYS IT EXITED MULTI-YEAR LONG POSITION IN MYLAN DURING QUARTER WITH A SMALL LOSS.GREENLIGHT CAPITAL SAYS ADDED TWO MEDIUM SIZED LONG POSITIONS THIS QUARTER, ALTICE USA & BT GROUP.GREENLIGHT CAPITAL SAYS EXITED LONG POSITION IN MICRON WITH 66 PERCENT GAIN OVER 1-1/2 YEAR.GREENLIGHT CAPITAL SAYS EXITED TWITTER WITH 78 PERCENT GAIN OVER 8 MONTHS.GREENLIGHT CAPITAL SAYS EXITED OUR SHORT POSITION IN TRANSDIGM GROUP WITH A MEDIUM LOSS.GREENLIGHT CAPITAL SAYS AT QUARTER-END, LARGEST DISCLOSED LONG POSITIONS WERE AERCAP, BRIGHTHOUSE FINANCIAL, GENERAL MOTORS, GREEN BRICK PARTNERS AND GOLD.GREENLIGHT CAPITAL SAYS EXITED TWITTER AS IT BECAME WORRIED ABOUT REGULATORY RISKS AFFECTING ALL SOCIAL MEDIA COS.GREENLIGHT CAPITAL SAYS HAD AN AVERAGE EXPOSURE OF 106 PERCENT LONG AND 74 PERCENT SHORT.GREENLIGHT CAPITAL SAYS "IN THINKING THROUGH TESLA MORE, IT BRINGS US BACK TO LEHMAN".  Full Article

Photo

Bayer CEO says has not had contact with activist investor Elliott

DUESSELDORF Bayer Chief Executive Werner Baumann said on Monday he has not had any contact with Elliott Management, following a Reuters report which said the U.S.-based activist investor had taken a position in the German pharmaceuticals giant.